Attention deficit/hyperactivity disorder and methylphenidate: A review of height/weight, cardiovascular, and somatic complaint side effects

Three classes (height/weight, cardiovascular, and somatic complaints) of treatment emergent symptoms (side effects) associated with methylphenidate (MPH) therapy for children with attention deficit/hyperactivity disorder (ADHD) are reviewed. The more easily quantifiable side effects (e.g., blood pressure [BP], heart rate [HR], height/weight) are mostly transient, dose-dependent, easily rectified with dosage adjustments, and considered minor from a clinical perspective considering the breadth and level of improvement in behavior and cognitive functioning observed in most children. Previously reported somatic complaints associated with psychostimulant therapy may reflect symptoms occurring prior to initiation of treatment and require additional study.